STAAR Surgical reported third-quarter 2026 net sales of $83.4 million, down 12% from $94.7 million a year earlier, and net income of $5.6 million, or $0.11 per diluted share, versus $8.9 million, or $0.18, in the prior-year quarter. The prior-year quarter included $25.9 million of deferred China sales; excluding that, third-quarter net sales rose 21%, and the company said it expects gross margin to improve in the fourth quarter. The Board also authorized a share repurchase of up to $50 million, and the company reported no outstanding debt.
Net sales were $83.4 million, down 12% from $94.7 million; up 21% excluding $25.9 million of deferred China sales recognized in the third quarter of 2025.
Gross profit margin was 70.9%, compared with 82.2% in the prior-year quarter, which included deferred China revenue with no cost of sales.
Net income was $5.6 million, or $0.11 per diluted share, versus $8.9 million, or $0.18, a year earlier.
In September 2026 the Board authorized repurchases of up to $50 million of common stock; cash and investments were $206.4 million as of October 2, 2026, with no outstanding debt.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From STAAR Surgical Company's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2026
$239.44M
-23.7%
$-1.62
—
-33.6%
FY2024
$313.90M
-2.6%
$-0.41
-195.3%
-6.4%
FY2023
$322.42M
+34.7%
$0.43
-46.2%
6.6%
FY2022
$239.44M
+3.9%
$0.80
+42.9%
16.6%
FY2021
$230.47M
+945.1%
$0.56
+366.7%
11.9%
Frequently asked questions
When is STAAR Surgical's next earnings date?
STAAR Surgical has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did STAAR Surgical earn last quarter?
For the quarter ended Oct 2026, STAAR Surgical reported diluted EPS of $0.11 (-38.9% year over year) on revenue of $83.41M (-12.0%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.